Cardiometabolic Disease Market Forecast to 2031 - COVID
Posted by pooja on August 25th, 2022
The global cardiometabolic disease market is estimated to witness a stupendous growth rate in the coming years. The high incidence of type 2 diabetes mellitus due to changing lifestyles, genetic predisposition, and obesity have collectively increased the risk of cardiometabolic diseases amongst the global population. The incidence of these cluster of diseases finally leading to cardiometabolic syndrome is expected to be high in developed countries, where obesity is on the rise.
Cardiometabolic disease, commonly known as Reaven’s syndrome, is characterized by a group of abnormalities and symptoms that include abdominal obesity, high-blood pressure, poor cholesterol profile (LDL), dyslipidemia (high serum triglycerides), and high plasma glucose. Individuals suffering from cardiometabolic syndrome are prone to a number of diseases such as type 2 diabetes, coronary artery disease (CAD), cardiovascular disease (CVD), stroke, heart failure, and hypertension.
Some of the leading players of the global Cardiometabolic Disease Market for 2016 were Torrent Pharmaceutical Ltd., Cardax Pharmaceuticals, Inc., Abeille Pharmaceuticals, Inc., VivaCell Biotechnology Espana S.L., Spherix Incorporated, and Indus Biotech Private Limited.
Get Sample Copy Of This Report: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=73
About TMR Research
Like it? Share it!
About the Authorpooja
Joined: July 27th, 2022
Articles Posted: 199
More by this author